Clostridium difficile

Fidaxomicin reduces C. diff recurrence

Compared to vancomycin, patients treated with fidaxomicin for Clostridium difficile infection were significantly less likely to have a recurrence. Read more here.

The catastrophic threat of Clostridium difficile

Clostridium difficile (C. diff) is becoming a common microorganism in the healthcare systems and poses a catastrophic threat to the United States. It costs the healthcare system up…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Take the 2024 Nursing Trends and Salary Survey, available now through November 1st 2024

See Past Results
cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

What is the primary purpose of a 3-minute foot assessment in patients with comorbidities such as diabetes or peripheral arterial disease?